Back to Search
Start Over
CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
- Source :
- Zhongliu Fangzhi Yanjiu, Vol 46, Iss 1, Pp 72-75 (2019)
- Publication Year :
- 2019
- Publisher :
- Magazine House of Cancer Research on Prevention and Treatment, 2019.
-
Abstract
- Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, immune therapy, molecular targeted agents and the other therapeutics could overcome its resistance and improve clinical benefits. CDK4/6 inhibitors-based combinational therapeutics provides a promising window for human cancer treatment.
Details
- Language :
- Chinese
- ISSN :
- 10008578
- Volume :
- 46
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Zhongliu Fangzhi Yanjiu
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.5706a13b62504d228bd19266acf48efe
- Document Type :
- article
- Full Text :
- https://doi.org/10.3971/j.issn.1000-8578.2019.18.0906